Study | No. AU Attacks/100 Patient-yrs During Placebo | No. AU Attacks/100 Patient-yrs During Anti-TNF | Reduction, % | Followup, Patient-yrs (No. patients) | Mean Patient-yrs/Patient |
---|---|---|---|---|---|
Braun1, 2005 | 16 | ETN 8 | 49 | 430 (297) | 1.4 |
(RCT + OL phase) | IFX 3 | 78 | 146 (90) | 1.6 | |
Sieper28, 2010 | 19 | ETN 12 | 38 | 1137 (1074) | 1.1 |
(RCT + OL phase) | |||||
Before anti-TNF | |||||
Rudwaleit30, 2009 | 15 | ADA 7 | 51 | 363 (1250) | 0.3 |
Current study | 68 | ADA 14 | 80 | 139 (77) | 1.8 |
RCT: randomized controlled trial; OL: open-label phase; ETN: etanercept; IFX: infliximab; ADA: adalimumab.